Outcome of the Board meeting held on 15.01.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs' board, meeting on 15 January 2026, approved two preferential allotments at Rs. 89 per unit: (1) up to 23,60,065 convertible warrants to 9 promoter-group allottees, and (2) up to 25,96,935 equity shares to 31 allottees including promoters and non-promoters. The warrants must convert into equal equity shares within 18 months or the upfront amount is forfeited. Combined, the two issues could raise roughly Rs. 44 crore (Rs. 21 cr from warrants + Rs. 23 cr from equity shares). Post-allotment, promoter holding will be 51.52% and public holding 48.48%. Shareholder approval will be sought at an EGM scheduled for 12 February 2026 via video conference.
The Rs. 89 issue price acts as a floor for the stock in the near term. The preferential issues will dilute existing shareholders modestly, but promoter confidence in raising their stake signals long-term commitment. Watch the stock around the 12 February EGM date for sentiment cues.